NF-κB regulatory mechanisms in alveolar macrophages from patients with acute respiratory distress syndrome

Shock

Volumn 13, Issue 2, 2000, Pages 85-91

  Moine, Pierre ^a,c   McIntyre, Robert ^a   Schwartz, Michael D ^a   Kaneko, Debra ^a   Shenkar, Robert ^a   Le Tulzo, Yves ^a   Moore, Ernest E ^b   Abraham, Edward ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c BICÊTRE HOSPITAL   (France)

Author keywords

Acute lung injury; Bel 3; c Rel; I B like proteins; I B ; I B ; I B ; p105; p50; p65; Rel NF B family of transcription factory

Indexed keywords

DNA BINDING PROTEIN; I KAPPA B; I KAPPA B BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NFKB1 PROTEIN, HUMAN; ONCOPROTEIN; P50B P97 PROTEIN, HUMAN; P50B-P97 PROTEIN, HUMAN; PROTEIN PRECURSOR; PROTO ONCOGENE PROTEIN BCL 3; PROTO-ONCOGENE PROTEIN BCL-3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CELL NUCLEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPLASM; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOLOGY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; METABOLISM; MIDDLE AGED;

BRONCHOALVEOLAR LAVAGE; CELL NUCLEUS; CYTOPLASM; DNA-BINDING PROTEINS; FEMALE; HUMANS; I-KAPPA B PROTEINS; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-REL; RESPIRATORY DISTRESS SYNDROME, ADULT; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTORS;

EID: 0034132919     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200013020-00001     Document Type: Article

References (38)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R: The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824, 1994.
2. Milberg JA, Davis DR, Steinberg KP, Hudson LD: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. J Am Med Assoc 273:306-309, 1995.
3. Donnelly SC, Strieter RM, Kunkel SL, Waltz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, Haslett C: Interleukin-8 and the development of adult respiratory distress syndrome in at-risk patient groups. Lancet 341: 643-647, 1993.
4. Jacobs RF, Tabor DR, Burks AW, Campbell DG: Elevated interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am Rev Respir Dis 140:1686-1692, 1989.
5. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM: High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 145: 1016-1022, 1992.
6. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A: Inflammatory cytokines in BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest 108:1303-1314, 1995.
7. Millar AB, Singer M, Meager A, Foley NM, Johnson NM, Rook GAW: Tumor necrosis factor in bromchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet 2:712-714, 1989.
8. Grilli M, Chiu JJS, Lenardo MJ: NF-κB and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol 143:1-62, 1993.
9. Baldwin AS: The NF-κ B and IκB proteins: new discoveries and insights. Annu Rev Immunol 14:649-681, 1996.
10. Pahl HL, Baeuerle PA: Oxygen and the control of gene expression. Bioessays 16:497-502, 1994.
11. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E: Nuclear factor-κB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 24:1285-1292, 1996.
12. Baeuerle PA, Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141-179, 1994.
13. Grimm S, Baeuerle PA: The inducible transcription factor NF-κB: structure-function relationship of its protein subunits. Biochem J 290:297-308, 1993.
14. Brown K, Park S, Kanno T, Franzoso G, Siebenlist U: Mutual regulation of the transcriptional activator NF-κB and its inhibitor, IκBα. Proc Natl Acad Sci USA 90:2532-2536, 1993.
15. Sun S, Ganchi PA, Ballard DA, Greene WC: NF-κB controls expression of inhibitory IκBα: evidence for an inducible autoregulatory pathway. Science 259:1912-1915, 1993.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13:818-829, 1985.
17. Baker SP, O'Neill B, Long WB: The Injury Severity Score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 14:187-196, 1974.
18. McAnena OJ, Moore FA, Moore EE, Mattox KL, Marx JA, Pepe P: Invalidation of the APACHE II scoring system for patients with acute trauma. J Trauma 33:504-507, 1992.
19. Hertz MI: Minimizing the risk of bronchoscopy during mechanical ventilation. Chest 104:1319-1320, 1993.
20. Steinberg KP, Mitchell DR, Maunder RJ, Milberg JA, Whitcomb ME, Hudson LD: Safety of bronchoalveolar lavage in patients with adult respiratory distress syndrome. Am Rev Respir Dis 148:556-561, 1993.
21. Chelen CJ, Fang Y, Freeman GJ, Secrist H, Marshall JD, Hwang PT, Frankel LR, Dekruyff RH: Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules. J Clin Invest 95:1415-1421, 1995.
22. Shenkar R, Abraham E: Plasma from hemorrhaged mice activates CREB and increases cytokine expression in lung mononuclear cells through a xanthine oxidase-dependent mechanism. Am J Respir Cell Mol Biol 14: 198-206, 1996.
23. Shenkar R, Schwartz MD, Terada LS, Repine JE, Mc Cord J, Abraham E: Hemorrhage activates NF-κB in murine lung mononuclear cells in vivo. Am J Physiol 270:L729-L735, 1996.
24. Dignam JD, Martin PL, Shatry BS, Roeder RF: Eukariotic gene transcription with purified components. Methods Enzymol 101:582-598, 1983.
25. Qian J, Bours V, Manischewitz J, Blackburn R, Siebenlist U, Golding H: Chemically selected subclones of the CEM cell line demonstrate resistance to HIV-1 infection resulting from a selective loss of NF-κB DNA binding proteins. J Immunol 152:4183-8191, 1994.
26. 2+ dependence and differential half-site recognition. J Biol Chem 266:252-260, 1991.
27. Laemmli KK: Cleavage structural proteins during the assembly of the head of bacteriophage T4. Nature 27:680-685, 1970.
28. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Erlbaum Associates, 1988.
29. Brown BW, Hollander M: Statistics: A Biomedical Introduction. New York: John Wiley & Sons, 1977.
30. Rice NR, Ernst MK: In vivo control of NF-κB activation by IκBα. EMBO J 12:4685-4695, 1993.
31. Hoffmann HP, Remy R, Scheidereit C, Van Loon APGM: Maintenance of NF-κB activity is dependent on protein synthesis and the continuous presence of external stimuli. Mol Cell Biol 11:259-266, 1991.
32. Kollef MH, Eisenberg PR, Ohlendorf MF, Wick MR: The accuracy of elevated concentrations of endotoxin in bronchoalveolar lavage fluid for the rapid diagnosis of gram-negative pneumonia. Am J Respir Crit Care Med 154:1020-1028, 1996.
33. Hoch RC, Rodriguez R, Manning T, Bishop M, Mead P, Shoemaker WC, Abraham E: Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med 21:839-845, 1993.
34. Moore FA, Moore EE, Poggetti RS, Read RA: Postinjury shock and early bacteremia. Arch Surg 127:893-898, 1992.
35. Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW: In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation. J Immunol 157:1630-1637, 1996.
36. Chiao PJ, Miyamoto S, Verma IM: Autoregulation of IκBα activity. Proc Natl Acad Sci USA 91:28-32, 1994.
37. Imbert V, Rupee RA, Livolsi A, Pahl HL, Britta-Mareen Traenckner E, Muller-Dieskmann C, Farahifar D, Rossi B, Auberger P, Bauerle PA, Peyron JF: Tyrosine phosphorylation of IκBα activates NF-κB without proteolytic degradation of IκBα. Cell 86:787-798, 1996.
38. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U: The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB mediated inhibition. Nature 359:339-342, 1992.